159P Peripheral T-lymphocytes senescence and response to neoadjuvant therapy (NAT) in operable breast cancer (BC)

BackgroundIncreasing evidence suggests a link between T-cell senescence and tumor prognosis. In particular, high levels of circulating senescent T-lymphocytes have been correlated with worse response to treatment. this perspective, therapeutic approach aimed at clearance is regarded as an innovative strategy currently under investigation in pre-clinical clinical models. The purpose the present study characterize impact predictive factor patients operable BC treated NAT, according different biological subtypes.MethodsSixty-nine diagnosed early stage candidate preoperative therapy enrolled so far. CD3+ T cells were isolated from peripheral blood (PB) by Ficoll stratification baseline after NAT (before surgery). cyclin-dependent kinase inhibitor (CDKi) p16 was used RT-PCR. RPLP-0 gene housekeeping healthy controls for data normalization (2-ΔΔCt). Mann-Whitney test (Wilcoxon rank sum test) highlight possible association expression NAT.ResultsCurrently, 48 tested NAT. Of these, 17 (35%) triple negative (TN), 10 (21%) Luminal 21 (44%) HER2+. Overall, 26 out (54%) achieved pathological complete (pCR). No significant difference relative observed who pCR: (4.87±1.33 vs 6.01±1.25; p=0.0649). residual disease (RD), increase (1.76±0.46 5.54±0.85; p=<0.0001).ConclusionsThese preliminary results suggest that p16-positive T-cells Analyses will be presented subtypes.Legal entity responsible studyFrancesca D'Avanzo.FundingHas not received any funding.DisclosureAll authors declared no conflicts interest. subtypes. Increasing MethodsSixty-nine Sixty-nine ResultsCurrently, p=<0.0001). Currently, ConclusionsThese These